Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT ID: NCT05607550
Last Updated: 2025-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
398 participants
INTERVENTIONAL
2023-06-01
2028-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
NCT05466149
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
NCT06652048
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
NCT06674343
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT05334277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
furmonertinib 240 mg
furmonertinib 240 mg oral, daily
furmonertinib tablet
furmonertinib 160 mg
furmonertinib 160 mg oral, daily
furmonertinib tablet
platinum-based chemotherapy
carboplatin or cisplatin based on investigator's choice + pemetrexed intravenously
platinum-based chemotherapy
(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
furmonertinib 240 mg oral, daily
furmonertinib tablet
furmonertinib 160 mg oral, daily
furmonertinib tablet
platinum-based chemotherapy
(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation in tumor tissue or blood from local or central testing.
* No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).
* Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease (excluding EGFR-TKIs) must have experienced a treatment free interval of at least 12 months.
* Patients with a history of treated CNS metastases or new asymptomatic CNS metastases are eligible.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allist Pharmaceuticals, Inc.
INDUSTRY
ArriVent BioPharma, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Morgan Lam
Role: STUDY_DIRECTOR
ArriVent BioPharm
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arrivent Investigative Site
Daphne, Alabama, United States
Arrivent Investigative Site
Yuma, Arizona, United States
Arrivent Investigative Site
Fayetteville, Arkansas, United States
Arrivent Investigative Site
Beverly Hills, California, United States
Arrivent Investigative Site
Fullerton, California, United States
Arrivent Investigative Site
Long Beach, California, United States
Arrivent Investigative Site
Los Alamitos, California, United States
Arrivent Investigative Site
Napa, California, United States
Arrivent Investigative Site
Orange, California, United States
Arrivent Investigative Site
Orange, California, United States
Arrivent Investigative site
Sacramento, California, United States
Arrivent Investigative Site
San Diego, California, United States
Arrivent Investigative Site
Santa Barbara, California, United States
Arrivent Investigative Site
Santa Monica, California, United States
Arrivent Investigative Site
Santa Rosa, California, United States
Arrivent Investigative Site
Whittier, California, United States
Arrivent Investigative Site
Hartford, Connecticut, United States
Arrivent Investigative Site
Norwich, Connecticut, United States
Arrivent Investigative Site
Fort Myers, Florida, United States
Arrivent Investigative Site
St. Petersburg, Florida, United States
Arrivent Investigative Site
The Villages, Florida, United States
Arrivent Investigative Site
Peoria, Illinois, United States
Arrivent Investigative Site
Rolling Meadows, Illinois, United States
Arrivent Investigative Site
Fort Wayne, Indiana, United States
Arrivent Investigative Site
Indianapolis, Indiana, United States
Arrivent Investigative Site
South Bend, Indiana, United States
Arrivent Investigative Site
Bethesda, Maryland, United States
Arrivent Investigative Site
Frederick, Maryland, United States
Arrivent Investigative Site
Rockville, Maryland, United States
Arrivent Investigative Site
Fairhaven, Massachusetts, United States
Arrivent Investigative Site
Lansing, Michigan, United States
Arrivent Investigative Site
Bolivar, Missouri, United States
Arrivent Investigative Site
Kansas City, Missouri, United States
Arrivent Investigative Site
Saint Joseph, Missouri, United States
Arrivent Investigative Site
St Louis, Missouri, United States
Arrivent Investigative Site
Omaha, Nebraska, United States
Arrivent Investigative Site
Belleville, New Jersey, United States
Arrivent Investigative Site
Englewood, New Jersey, United States
Arrivent Investigative Site
Florham Park, New Jersey, United States
Arrivent Investigative Site
The Bronx, New York, United States
Arrivent Investigative Site
Goldsboro, North Carolina, United States
ArriVent Investigative Site
Pinehurst, North Carolina, United States
Arrivent Investigative Site
Canton, Ohio, United States
Arrivent Investigative Site
Cincinnati, Ohio, United States
ArriVent Investigative Site
Cincinnati, Ohio, United States
Arrivent Investigative Site
Cleveland, Ohio, United States
Arrivent Investigative Site
Columbus, Ohio, United States
Arrivent Investigative Site
Oklahoma City, Oklahoma, United States
Arrivent Investigative Site
Tulsa, Oklahoma, United States
Arrivent Investigative Site
Salem, Oregon, United States
Arrivent Investigative Site
Gettysburg, Pennsylvania, United States
ArriVent Investigative Site
Langhorne, Pennsylvania, United States
Arrivent Investigative Site
York, Pennsylvania, United States
Arrivent Investigative Site
Greenville, South Carolina, United States
Arrivent Investigative Site
Sioux Falls, South Dakota, United States
Arrivent Investigative Site
Memphis, Tennessee, United States
ArriVent Investigative Site
Nashville, Tennessee, United States
Arrivent Investigative Site
Abilene, Texas, United States
ArriVent Investigative Site
Austin, Texas, United States
Arrivent Investigative Site
Houston, Texas, United States
Arrivent Investigative Site
Plano, Texas, United States
Arrivent Investigative Site
Ogden, Utah, United States
Arrivent Investigative Site
Salt Lake City, Utah, United States
ArriVent Investigative Site
Fairfax, Virginia, United States
Arrivent Investigative Site
Fredericksburg, Virginia, United States
Arrivent Investigative Site
Bellingham, Washington, United States
Arrivent Investigative Site
Spokane Valley, Washington, United States
Arrivent Investigative Site
Tacoma, Washington, United States
Arrivent Investigative Site
Appleton, Wisconsin, United States
ArriVent Investigative Site
Heidelberg, Victoria, Australia
Arrivent Investigative Site
Blacktown, , Australia
Arrivent Investigative Site
St Leonards, , Australia
Arrivent Investigative Site
Woolloongabba, , Australia
ArriVent Investigative Site
Salvador, Estado de Bahia, Brazil
ArriVent Investigative Site
Belo Horizonte, Minas Gerais, Brazil
ArriVent Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
ArriVent Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
ArriVent Investigative Site
Pelotas, Rio Grande do Sul, Brazil
ArriVent Investigative Site
Porto Alegre, Rio Grande, Brazil
ArriVent Investigative Site
Blumenau, SC Cep, Brazil
ArriVent Investigative Site
São José do Rio Preto, São Paulo, Brazil
ArriVent Investigative Site
São Paulo, São Paulo, Brazil
ArriVent Investigative Site
Liberdade, São Paulo/SP, Brazil
ArriVent Investigative Site
Taubaté, Taubate SP, Brazil
ArriVent Investigative Site
Porto Alegre, , Brazil
ArriVent Investigative Site
Edmonton, Alberta, Canada
ArriVent Investigative Site
Toronto, Ontario, Canada
Allist Investigative Site
Beijing, Beijing Municipality, China
Allist Investigative Site
Meizhou, Guangdong, China
Allist Investigative Site
Xuhui, Hai City, China
Allist Investigative Site
Hangzhou, Hangzhou, China
Allist Investigative Site
Cangzhou, Hebei, China
Allist Investigative Site
Shushan, Hefei, China
Allist Investigative Site
Zhengzhou, Henan, China
Allist Investigative Site
Changchun, Jilin, China
Allist Investigative Site
Weihai, Lingang Economic and Technological Development Zo, China
Allist Investigative Site
Nanning, Nanning, China
Allist Investigative Site
Yangpu, Shanghai Municipality, China
Allist Investigative Site
Xi’an, Shanxi, China
Allist Investigative Site
Taiyuan, Taiyuan, China
Allist Investigative Site
Kunming, Yunnan, China
Allist Investigative Site
Zhejiang, Zhejiang, China
Allist Investigative Site
Anyang, , China
Allist Investigative Site
Changchun, , China
Allist Investigative Site
Changsha, , China
Allist Investigative Site
Changsha, , China
Allist Investigative Site
Chengdu, , China
Allist Investigative Site
Chenzhou, , China
Allist Investigative Site
Chongqing, , China
Allist Investigative Site
Guangzhou, , China
Allist Investigative Site
Guangzhou, , China
Allist Investigative Site
Harbin, , China
Allist Investigative Site
Hefei, , China
Allist Investigative Site
Huai'an, , China
Allist Investigative Site
Huizhou, , China
Allist Investigative Site
Jinan, , China
Allist Investigative Site
Jinan, , China
Allist Investigative Site
Jining, , China
Allist Investigative Site
Lanzhou, , China
Allist Investigative Site
Lishui, , China
Allist Investigative Site
Luoyang, , China
Allist Investigative Site
Nanchang, , China
Allist Investigative Site
Nanchang, , China
Allist Investigative Site
Nanjing, , China
Allist Investigative Site
Ningbo, , China
Allist Investigative Site
Shanghai, , China
Allist Investigative Site
Shantou, , China
Allist Investigative Site
Shenyang, , China
Allist Investigative Site
Shenzhen, , China
Allist Investigative Site
Taiyuan, , China
Allist Investigative Site
Tianjin, , China
Allist Investigative Site
Weihui, , China
Allist Investigative Site
Wuhan, , China
Allist Investigative Site
Xiamen, , China
Allist Investigative Site
Xianyang, , China
Allist Investigative Site
Xinxiang, , China
Allist Investigative Site
Xuzhou, , China
Allist Investigative Site
Zhengzhou, , China
Arrivent Investigative Site
Caen, , France
Arrivent Investigative Site
Lyon, , France
Arrivent Investigative Site
Lyon, , France
Arrivent Investigative Site
Marseille, , France
Arrivent Investigative Site
Toulouse, , France
Arrivent Investigative Site
Villejuif, , France
ArriVent Investigative Site
Beersheba, , Israel
ArriVent Investigative Site
Haifa, , Israel
ArriVent Investigative Site
Jerusalem, , Israel
ArriVent Investigative Site
Rozzano, Milan, Italy
ArriVent Investigative Site
Aviano, PN, Italy
ArriVent Investigative Site
Roma, Rome, Italy
ArriVent Investigative Site
Bari, , Italy
Arrivent Investigative Site
Meldola, , Italy
ArriVent Investigative Site
Milan, , Italy
ArriVent Investigative Site
Kurume, Fukuoka, Japan
Arrivent Investigative Site
Akashi, , Japan
Arrivent Investigative Site
Hirakata, , Japan
Arrivent Investigative Site
Kashiwa, , Japan
Arrivent Investigative Site
Nagoya, , Japan
Arrivent Investigative Site
Ōsaka-sayama, , Japan
Arrivent Investigative Site
Sapporo, , Japan
Arrivent Investigative Site
Sendai, , Japan
Arrivent Investigative Site
Shizuoka, , Japan
Arrivent Investigative Site
Tokyo, , Japan
ArriVent Investigative Site
Tokyo, , Japan
Arrivent Investigative Site
Ube, , Japan
Arrivent Investigative Site
Yokohama, , Japan
ArriVent Investigative Site
George Town, Pulau Pinang, Malaysia
Arrivent Investigative Site
Cheras, , Malaysia
Arrivent Investigative Site
Kota Bharu, , Malaysia
Arrivent Investigative Site
Kuala Lumpur, , Malaysia
Arrivent Investigative Site
Kuching, , Malaysia
ArriVent Investigative Site
Tuxtla Gutiérrez, Chiapas, Mexico
ArriVent Investigative Site
Mexico City, Mexico City, Mexico
Arrivent Investigative Site
Amsterdam, , Netherlands
Arrivent Investigative Site
Harderwijk, , Netherlands
Arrivent Investigative Site
Cebu, , Philippines
Arrivent Investigative Site
Davao City, , Philippines
ArriVent Investigative Site
Manila, , Philippines
Arrivent Investigative Site
Pasig, , Philippines
ArriVent Investigative Site
Singapore, , Singapore
Arrivent Investigative Site
Singapore, , Singapore
ArriVent Investigative Site
Jungni I Gu, Seoul, South Korea
Arrivent Investigative Site
Busan, , South Korea
Arrivent Investigative Site
Hwasun, , South Korea
Arrivent Investigative Site
Seoul, , South Korea
Arrivent Investigative Site
Seoul, , South Korea
Arrivent Investigative Site
Seoul, , South Korea
Arrivent Investigative Site
Seoul, , South Korea
ArriVent Investigative Site
Málaga, Malaga, Spain
Arrivent Investigative Site
A Coruña, , Spain
Arrivent Investigative Site
Barcelona, , Spain
ArriVent Investigative Site
Madrid, , Spain
Arrivent Investigative Site
Valencia, , Spain
Arrivent Investigative Site
Chang-hua, , Taiwan
Arrivent Investigative Site
Kaohsiung City, , Taiwan
ArriVent Investigative Site
Kaohsiung City, , Taiwan
ArriVent Investigative Site
Taichung, , Taiwan
Arrivent Investigative Site
Tainan City, , Taiwan
Arrivent Investigative Site
Taipei, , Taiwan
Arrivent Investigative Site
Bangkok, , Thailand
Arrivent Investigative Site
Bangkok, , Thailand
Arrivent Investigative Site
Bangkok, , Thailand
Arrivent Investigative Site
Hat Yai, , Thailand
ArriVent Investigative Site
Guildford, Surrey, United Kingdom
Arrivent Investigative Site
Bebington, Wirral, United Kingdom
ArriVent Investigative Site
London, , United Kingdom
ArriVent Investigative Site
Manchester, , United Kingdom
ArriVent Investigative Site
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502977-41-00
Identifier Type: CTIS
Identifier Source: secondary_id
FURMO-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.